Dato-DXd new BLA submitted, NSQ BLA withdrawn
12 November 2024
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small…
77,250€
-0,96%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
9M and Q3 2024 Results
AstraZeneca
12 November 2024
9M and Q3 2024 results
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum
Revenue and EPS…
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second…
AstraZeneca’s China-Fueled Plunge May Be Difficult to Shake Off
AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday…
AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
…